Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Total Non-Current Liabilities (2023 - 2024)

Artiva Biotherapeutics (ARTV) has disclosed Total Non-Current Liabilities for 2 consecutive years, with $22.9 million as the latest value for Q4 2024.

  • Quarterly Total Non-Current Liabilities fell 10.73% to $22.9 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $22.9 million through Dec 2024, down 10.73% year-over-year, with the annual reading at $22.9 million for FY2024, 10.73% down from the prior year.
  • Total Non-Current Liabilities for Q4 2024 was $22.9 million at Artiva Biotherapeutics, down from $24.5 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $50.5 million in Q2 2024, with the low at $22.9 million in Q4 2024.